Bacterial Prostatitis

Total Page:16

File Type:pdf, Size:1020Kb

Bacterial Prostatitis REVIEW CURRENT OPINION Bacterial prostatitis Bradley C. Gill a,b and Daniel A. Shoskesa,b Purpose of review The review provides the infectious disease community with a urologic perspective on bacterial prostatitis. Specifically, the article briefly reviews the categorization of prostatitis by type and provides a distillation of new findings published on bacterial prostatitis over the past year. It also highlights key points from the established literature. Recent findings Cross-sectional prostate imaging is becoming more common and may lead to more incidental diagnoses of acute bacterial prostatitis. As drug resistance remains problematic in this condition, the reemergence of older antibiotics such as fosfomycin, has proven beneficial. With regard to chronic bacterial prostatitis, no clear clinical risk factors emerged in a large epidemiological study. However, bacterial biofilm formation has been associated with more severe cases. Surgery has a limited role in bacterial prostatitis and should be reserved for draining of a prostatic abscess or the removal of infected prostatic stones. Summary Prostatitis remains a common and bothersome clinical condition. Antibiotic therapy remains the basis of treatment for both acute and chronic bacterial prostatitis. Further research into improving prostatitis treatment is indicated. Keywords acute bacterial prostatitis, bacterial prostatitis, category I prostatitis, category II prostatitis, chronic bacterial prostatitis, male pelvic pain INTRODUCTION and August 2015 were identified among the first Prostatitis is a bothersome condition but carries 600 search results. The titles of English language potential for serious morbidity from sepsis, abscess, articles were examined and those pertaining to non- or fistula if insufficiently managed. Nearly one in six bacterial prostatitis, chronic pelvic pain, and animal men report a history of prostatitis, resulting in over or basic science models were excluded. After this, a $84 million in annual medical expenditure [1,2]. total of 38 articles related to acute and chronic Prostatitis exhibits a bimodal peak of incidence, bacterial prostatitis were reviewed. with men between 20 and 40 years of age or older than 60 years afflicted most commonly [3]. The Prostatitis categorization scheme reasons for this distribution or potential for con- The National Institutes of Health consensus classi- founding by sexually transmitted infections are fication of prostatitis (Table 1) divides the condition unknown. In over 90% of men with fever and uri- into four categories based upon clinical presentation nary symptoms, prostatitis is the underlying con- [7]. These include acute (category I) and chronic dition in the absence of pyelonephritis symptoms (category II) bacterial prostatitis, as well as chronic [4]. With that, prostatitis accounts for nearly 8% of prostatitis/pelvic pain syndrome (category III) and urologist visits [5]. Overall, prostatitis remains a common condition and research to improve its a management would be beneficial. Department of Urology, Glickman Urological and Kidney Institute and bLerner College of Medicine, Education Institute, Cleveland Clinic, This review provides a distillation of notable Cleveland, Ohio, USA additions to the literature on prostatitis over the Correspondence to Daniel A. Shoskes, MD, Department of Urology, past year. It builds upon the journal’s February 2014 Glickman Urological and Kidney Institute, Cleveland Clinic, Mail Stop & review [6 ]. Additionally, it provides a brief overview Q10–1, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Tel: +1 216 of prostatitis categorization. To complete this manu- 445 4757; fax: +1 216 444 0390; e-mail: [email protected] script, a PubMed query for ‘prostatitis’ was con- Curr Opin Infect Dis 2016, 29:86–91 ducted and articles dated between January 2014 DOI:10.1097/QCO.0000000000000222 www.co-infectiousdiseases.com Volume 29 Number 1 February 2016 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Bacterial prostatitis Gill and Shoskes (dysuria, urinary frequency, and urinary urgency), KEY POINTS and focal symptoms (pelvic or perineal pressure) Tailoring antibiotic treatment to culture-proven bacterial suggestive of prostatic involvement. Obstructive sensitivity is essential. urinary symptoms (weak stream, dribbling, and hesitancy) may also present, with urinary retention Any chosen antibiotic must penetrate the prostate and possible. Commonly, an intervention such as trans- reach therapeutic levels. rectal ultrasound-guided prostate biopsy may Antibiotic resistance is increasingly problematic. precede presentation. A sexual history may indicate the risk of a sexually transmitted infection. The indications for surgery in managing prostatitis Rectal examination almost always shows a ten- remain limited and very specific. der prostate. However, caution is warranted during digital rectal examination, as aggressive prostate palpation can release bacteria and inflammatory asymptomatic inflammatory prostatitis (category cytokines triggering an abrupt clinical decompensa- IV). To date, no data support the role of ‘hidden’ tion, thus contraindicating prostatic massage. infection or atypical organisms in category III or IV Serum laboratory assessment in CIP generally prostatitis. As such, there is no role for antibiotic reveals leukocytosis. During infection, prostate- therapy in these conditions, despite many patients specific antigen is invariably elevated and has no strongly believing a true infection exists and seeking diagnostic value for prostate cancer. Urinalysis and out multiple practitioners to diagnose one. urine culture are essential and blood cultures are indicated for a clinical suspicion of sepsis. All men should have a postvoid residual urine volume CATEGORY I PROSTATITIS: ACUTE measurement, as urinary retention may not be evi- BACTERIAL PROSTATITIS dent. Imaging with computed tomography (CT) Acute bacterial prostatitis or National Institutes of scan or ultrasound may reveal an enlarged and Health category I prostatitis (CIP) is defined as an inflamed heterogeneously appearing prostate, but acute urinary tract infection (UTI) with prostatic is not necessary unless concern for prostatic abscess involvement. Patients are usually febrile and may exists. present with urinary retention. Infection results from bacteria ascending the urethra, reflux of con- taminated urine into the prostatic ducts, direct Treatment introduction of bacteria during transrectal biopsy Successful treatment of CIP rests upon completion or urethral instrumentation, or hematogenous seed- of a sufficient course of appropriate antibiotic. The ing. Causative organisms include Escherichia coli in agent used must have demonstrated sensitivity most (65–80%) cases with Pseudomonas aeruginosa, against the infecting organism and also reach thera- Proteus mirabilis, Klebsiella spp., Serrita, and Enter- peutic levels in the prostate. During acute infection obacter spp. comprising the remainder [8–10]. With with prostatic inflammation, most antibiotics do impaired immunity, other microorganisms like penetrate the prostate (except nitrofurantoin) fungi (Cryptococcus spp. or Histoplasma spp.) and [11]. Without evidence of systemic disease or uri- Gram-positive (skin flora) bacteria, as well as Myco- nary retention, an oral antibiotic for 2–4 weeks is bacterium tuberculosis may be implicated. generally sufficient. Typical agents include a fluo- roquinolone or trimethoprim-sulfamethoxazole, Diagnosis with the quinolones reaching 3–4 times higher Men typically present with systemic symptoms intraprostatic concentrations than beta-lactam anti- (malaise, fevers, chills, and sweats), evidence of UTI biotics [10]. Repeat urine culture during therapy to assess for bacterial eradication is necessary, if clinical Table 1. National Institutes of Health consensus definition improvement is not seen, however, all cases of CIP and classification of prostatitis should have a confirmatory urine culture about 1 week following antibiotic completion to ensure National Institutes of Health consensus definition and bacteriologic cure. classification of prostatitis The acutely ill patient warranting hospitaliz- Category I Acute bacterial prostatitis ation for prostatitis will present a clinical picture Category II Chronic bacterial prostatitis of sepsis or a systemic inflammatory response syn- Category III Chronic prostatitis/chronic pelvic pain syndrome drome. Urinary tract decompression is often Category IV Asymptomatic inflammatory prostatitis required for urinary retention with grossly infected urine via a short-term indwelling urethral catheter, 0951-7375 Copyright ß 2016 Wolters Kluwer Health, Inc. All rights reserved. www.co-infectiousdiseases.com 87 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Urinary tract infections clean intermittent urethral catheterization, or a Urologic procedures may incite UTIs and pros- suprapubic catheter. Parenteral antibiotic therapy tatitis. A case report detailed a case of Salmonella is indicated until clinical stabilization is achieved, typhimurium prostatitis in a spinal cord injury with the chosen regimen guided by local anti- patient performing clean intermittent urethral biogram results. Typical treatment consists of catheterization and discussed the role of perineal empiric broad coverage with a fluoroquinolone colonization and bacterial seeding in such a setting and aminoglycoside, possibly in combination with [19]. A comparison of the clinical details
Recommended publications
  • Second and Third Generation Oral Fluoroquinolones
    Therapeutic Class Overview Second and Third Generation Oral Fluoroquinolones Therapeutic Class • Overview/Summary: The second and third generation quinolones are approved to treat a variety of infections, including dermatologic, gastrointestinal, genitourinary, respiratory, as well as several miscellaneous infections.1-10 They are broad-spectrum agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.11,12 The quinolones are most active against gram-negative bacilli and gram-negative cocci.12 Ciprofloxacin has the most potent activity against gram-negative bacteria. Norfloxacin, ciprofloxacin and ofloxacin have limited activity against streptococci and many anaerobes while levofloxacin and moxifloxacin have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.11-12 Gemifloxacin, levofloxacin and moxifloxacin are considered respiratory fluoroquinolones. They possess enhanced activity against Streptococcus pneumoniae while maintaining efficacy against Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens. Resistance to the quinolones is increasing and cross-resistance among the various agents has been documented. Two mechanisms of bacterial resistance have been identified. These include mutations in chromosomal genes (DNA gyrase and/or topoisomerase IV) and altered drug permeability across the bacterial cell membranes.11-12 Clinical Guidelines support
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Nitrofurantoin Administration for the Prevention of Short-Term Catheter
    Study Title: Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial ClinicalTrials.gov ID: NCT03287089 Date: July 6, 2018 STUDY OBJECTIVES Primary Objective To evaluate the efficacy of administration of nitrofurantoin prophylaxis after catheter discontinuation for the prevention of catheter-associated urinary tract infections in patients with postoperative short-term catheterization following pelvic reconstructive surgery. The primary outcome will be the treatment of clinically suspected and/or culture-proven UTI within 30 days of surgery. Secondary Objectives 1. To evaluate adverse outcomes related to study medications in each group 2. To evaluate medication compliance BACKGROUND Urinary tract infections (UTI) are the most common hospital-acquired infections, accounting for nearly 30% of cases of nosocomial infections and affecting nearly 1 million people per year.1-3 They account for nearly 8.1 million visits to health care providers and cost an estimated $1.6 billion a year in the United States alone.3,4 Following pelvic reconstructive and urinary incontinence surgery, UTIs are one of the most common complications.4,5 The baseline risk of UTI associated with pelvic floor surgery ranges between 5-35%, increasing greatly with catheterization.3 In women who are undergoing surgery for urinary incontinence, the risk of UTI ranges between 8.9% to 34%.4,6,7 Risk factors for urinary tract infections in women undergoing pelvic floor
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics
    16 November 2018 EMA/795349/2018 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) has endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: • to treat infections that might get better without treatment or are not severe (such as throat infections); • to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; • for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); • to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Le Infezioni in Medicina
    ISSN 1124-9390 LE INFEZIONI IN MEDICINA Position paper on uncomplicated cystitis and single dose antibiotic therapy with prulifloxacin www.infezmed.it Vol. 24 - Supplemento 1 - 2016 LE INFEZIONI IN MEDICINA Rivista trimestrale di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive Volume 24 - Suppl. n. 1 - 2016 O SOMMARIO Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche - Pavia Via Riviera 39 - 27100 Pavia Tel. 0382/526253 Fax 0382/423120 e-mail: [email protected] Registrazione Trib. di Milano n. 506 Introduction 3 del 6/9/2007 Silvano Esposito Direzione e Redazione Dipartimento di Medicina e Chirurgia Università degli Studi di Salerno Position paper 5 Via Allende, Baronissi, Salerno - Italy Tel. 0039 (089) 672420 on uncomplicated cystitis e-mail: [email protected] www.infezmed.it and single dose antibiotic therapy with prulifloxacin Direttore responsabile P.E. Zoncada Carlo Tascini, Rossella Nappi, Luigi Cormio, Massimo Lazzeri, Gabriele Alberto Saracino, Chiara Benedetto www.infezmed.it LE INFEZIONI IN MEDICINA A quarterly journal covering the etiological, epidemiological, diagnostic, clinical and therapeutic aspects of infectious diseases Editor in chief Esposito S. Editorial assistant Noviello S. Esposito I. ASSOCIATE EDITORS Dos Santos V.M. (Brasília, Brazil) Ece G. (Izmir, Turkey) HIV/AIDS Filice G. (Pavia, Italy) Andreoni M. Galli L. (Milan, Italy) Cauda R. Garau J. (Barcelona, Spain) Giacometti A. (Ancona, Italy) Viral hepatitis Gaeta G. B. Giamarellou H. (Athens, Greece) Taliani G. Gould I. (Aberdeen, UK) Gollapudi S. (Los Angeles, USA) Fungal infections Grossi P. (Varese, Italy) Viale P. Gyssens I. (Nijmegen, The Netherlands) Viscoli C. Heisig P. (Hamburg, Germany) Karamanou M.
    [Show full text]
  • Antibiotics Classification and Visual Target Sites for Bacterial Inhibition
    Advances in Pharmacology and Clinical Trials ISSN: 2474-9214 Antibiotics Classification and Visual Target Sites for Bacterial Inhibition Firoz Khan* Mini Review Department of Pharmaceutical Technology, Meerut Institute of Engineering and Volume 3 Issue 3 Technology, India Received Date: August 20, 2018 Published Date: September 06, 2018 *Corresponding author: Firoz Khan, M. Pharm (Pharmacology), Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), Delhi, India, Tel: +91-9012537941; Email: [email protected] Abstract We know that cell is the structural and functional unit of the entire microorganism. Some bacterial cell is also composed of cell wall and genetic material to do. If the microorganism invade in the human body it will became a disease state for the human. So, we did finds some target site of bacteria for killing or inhibit these invading bacteria’s. Some of the antibiotics are specific to act on cell wall such as Penicillin’s and Cephalosporin’s other are also available for inhibit the growth of gram negative or gram negative bacteria’ (Sulfamethoxazole, Quinolones etc). In this review the classification or target site action of the particular antibiotic are described for the accurate use of antibiotics to inhibit the growth of foreign particle in the human body. Keywords: Antibiotics; Target sites; Cell wall Introduction those that inhibit bacterial growth are termed bacteriostatic [3]. Mostly all of the antibiotics have effect The term antibiotic was coined from the word through inhibition of cell wall synthesis, leakage from cell “antibiosis” which literally means “against life”. In the wall, inhibit protein synthesis, destruction of bacterial past, antibiotics were considered to be organic DNA and metabolism related to bacteria.
    [Show full text]
  • Second and Third Generation Oral Fluoroquinolones
    Therapeutic Class Overview Second and Third Generation Oral Fluoroquinolones Therapeutic Class Overview/Summary: The second and third generation quinolones are approved to treat a variety of infections, including dermatologic, gastrointestinal, genitourinary, respiratory, as well as several miscellaneous infections.1-8 They are broad-spectrum agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.9,10 The quinolones are most active against gram-negative bacilli and gram-negative cocci.10 Ciprofloxacin has the most potent activity against gram-negative bacteria. Ciprofloxacin and ofloxacin have limited activity against streptococci and many anaerobes while levofloxacin and moxifloxacin have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.9,10 Gemifloxacin, levofloxacin and moxifloxacin are considered respiratory fluoroquinolones. They possess enhanced activity against Streptococcus pneumoniae while maintaining efficacy against Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens. Resistance to the quinolones is increasing and cross-resistance among the various agents has been documented. Two mechanisms of bacterial resistance have been identified. These include mutations in chromosomal genes (DNA gyrase and/or topoisomerase IV) and altered drug permeability across the bacterial cell membranes. 9,10 Clinical Guidelines support the use of fluoroquinolones
    [Show full text]
  • Prulifloxacin: a Review Focusing on Its Use Beyond Respiratory and Urinary Tract Infections Petros I
    Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections Petros I. Rafailidis, Konstantinos A. Polyzos, Konstantinos Sgouros, Matthew E. Falagas To cite this version: Petros I. Rafailidis, Konstantinos A. Polyzos, Konstantinos Sgouros, Matthew E. Fala- gas. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract in- fections. International Journal of Antimicrobial Agents, Elsevier, 2011, 37 (4), pp.283. 10.1016/j.ijantimicag.2010.11.032. hal-00679605 HAL Id: hal-00679605 https://hal.archives-ouvertes.fr/hal-00679605 Submitted on 16 Mar 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections Authors: Petros I. Rafailidis, Konstantinos A. Polyzos, Konstantinos Sgouros, Matthew E. Falagas PII: S0924-8579(10)00558-3 DOI: doi:10.1016/j.ijantimicag.2010.11.032 Reference: ANTAGE 3505 To appear in: International Journal of Antimicrobial Agents Received date: 11-11-2010 Accepted date: 19-11-2010 Please cite this article as: Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME, Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections, International Journal of Antimicrobial Agents (2010), doi:10.1016/j.ijantimicag.2010.11.032 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]